1. Home
  2. TKNO vs NYXH Comparison

TKNO vs NYXH Comparison

Compare TKNO & NYXH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Alpha Teknova Inc.

TKNO

Alpha Teknova Inc.

HOLD

Current Price

$2.90

Market Cap

138.1M

Sector

Health Care

ML Signal

HOLD

Logo Nyxoah SA

NYXH

Nyxoah SA

HOLD

Current Price

$3.31

Market Cap

152.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
TKNO
NYXH
Founded
1996
2009
Country
United States
Belgium
Employees
N/A
N/A
Industry
Medicinal Chemicals and Botanical Products
Medical/Dental Instruments
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
138.1M
152.8M
IPO Year
2021
2021

Fundamental Metrics

Financial Performance
Metric
TKNO
NYXH
Price
$2.90
$3.31
Analyst Decision
Strong Buy
Analyst Count
0
4
Target Price
N/A
$11.25
AVG Volume (30 Days)
118.7K
56.6K
Earning Date
05-07-2026
05-13-2026
Dividend Yield
N/A
N/A
EPS Growth
43.86
N/A
EPS
N/A
N/A
Revenue
$40,520,000.00
N/A
Revenue This Year
$8.27
$214.32
Revenue Next Year
$13.13
$124.13
P/E Ratio
N/A
N/A
Revenue Growth
7.35
N/A
52 Week Low
$1.91
$2.76
52 Week High
$7.48
$8.64

Technical Indicators

Market Signals
Indicator
TKNO
NYXH
Relative Strength Index (RSI) 52.33 45.83
Support Level $2.55 $2.76
Resistance Level $3.22 $3.32
Average True Range (ATR) 0.24 0.18
MACD 0.01 0.09
Stochastic Oscillator 44.37 59.66

Price Performance

Historical Comparison
TKNO
NYXH

About TKNO Alpha Teknova Inc.

Alpha Teknova Inc provides critical reagents that enable the discovery, development, and production of biopharmaceutical products such as drug therapies, novel vaccines, and molecular diagnostics. Its offer three product types: pre-poured media plates for cell growth and cloning; liquid cell culture media and supplements for cellular expansion; and molecular biology reagents for sample manipulation, resuspension, and purification. It derives key revenue from United States.

About NYXH Nyxoah SA

Nyxoah SA is a health-technology company focused on the development and commercialization of solutions and services to treat sleep-disordered breathing conditions. The company's solution platform is based on the Genio system, a CE-Mark validated, user-centered, bilateral neurostimulation therapy to treat moderate to severe Obstructive Sleep Apnea (OSA), the common sleep disordered breathing condition that is associated with increased mortality risk and comorbidities including cardiovascular diseases, depression and stroke.

Share on Social Networks: